Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Pallansch, Mark A ^a   Oberste, M Steven ^a   Lindsay Whitton, J ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974728213     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (455)

1. Abad FX, Pinto RM, Bosch A. Disinfection of human enteric viruses on fomites. FEMS Microbiol Lett 1997;156(1):107-111.
2. Abad FX, Pinto RM, Bosch A. Survival of enteric viruses on environmental fomites. Appl Environ Microbiol 1994;60(10):3704-3710.
3. Abed Y, Wolf D, Dagan R, et al. Development of a serological assay based on a synthetic peptide selected from the VP0 capsid protein for detection of human parechoviruses. J Clin Microbiol 2007;45(6):2037-2039.
4. Abzug M. Perinatal enterovirus infections. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: ASM Press, 1995:221-238.
5. Abzug MJ, Beam AC, Gyorkos EA, Levin MJ. Viral pneumonia in the first month of life. Pediatr Infect Dis J. 1990;9(12):881-885.
6. Abzug MJ, Cloud G, Bradley J, et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. Apr 2003;22(4):335-341.
7. Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rotbart HA. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis. 1995;20(5):1201-1206.
8. Ackermann WW, Fujioka RS, Kurtz HB. Cationic modulation of the inactivation of poliovirus by heat. Arch Environ Health. 1970;21(3):377-381.
9. Afif H, Sutter RW, Kew OM, et al. Outbreak of poliomyelitis in Gizan, Saudi Arabia: cocirculation of wild type 1 polioviruses from three separate origins. J Infect Dis. 1997;175(Suppl 1):S71-S75.
10. Ahn J, Jun ES, Lee HS, et al. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol. Jul 2005;79(13):8620-8624.
11. Alexander JP Jr, Chapman LE, Pallansch MA, Stephenson WT, Torok TJ, Anderson LJ. Coxsackievirus B2 infection and aseptic meningitis: a focal outbreak among members of a high school football team. J Infect Dis. 1993;167(5):1201-1205.
12. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696-1701.
13. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-k B by Toll-like receptor 3. Nature. 2001;413(6857):732-738.
14. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM. Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol. 1996;70:4632-4645.
15. Andreoletti L, Bourlet T, Moukassa D, et al. Enteroviruses can persist with or without active viral replication in cardiac tissue of patients with end-stage ischemic or dilated cardiomyopathy. J Infect Dis. 2000;182(4):1222-1227.
16. Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis 2009;102(6-7):559-568.
17. Anonymous. Deaths among children during an outbreak of hand, foot, and mouth disease-Taiwan, Republic of China, April-July 1998. MMWR Morbid Mortal Wkly Rep 1998;47(30):629-632.
18. Anonymous. Enterovirus Surveillance Report, 1970-1979. Atlanta: Centers for Disease Control, 1981.
19. Anonymous. From the Centers for Disease Control and Prevention. Final stages of poliomyelitis eradication-Western Pacific Region, 1997-1998. JAMA. 1999;281(18):1690-1691.
20. Archard LC, Khan MA, Soteriou BA, et al. Characterization of Coxsackie B virus RNA in myocardium from patients with dilated cardiomyopathy by nucleotide sequencing of reverse transcription-nested polymerase chain reaction products. Hum Pathol. 1998;29(6):578-584.
21. Archard LC, Richardson PJ, Olsen EG, Dubowitz V, Sewry C, Bowles NE. The role of Coxsackie B viruses in the pathogenesis of myocarditis, dilated cardiomyopathy and inflammatory muscle disease. Biochem Soc Symp. 1987;53:51-62.
22. Arnesjo B, Eden T, Ihse I, Nordenfelt E, Ursing B. Enterovirus infections in acute pancreatitis. Scand J Gastroenterol 1976;11(7):645-649.
23. Arola A, Kalimo H, Ruuskanen O, Hyypia T. Experimental myocarditis induced by two different coxsackievirus B3 variants: aspects of pathogenesis and comparison of diagnostic methods. J Med Virol. 1995;47:251-259.
24. Asturias EJ, Grazioso CF, Luna-Fineman S, Torres O, Halsey NA. Poliovirus excretion in Guatemalan adults and children with HIV infection and children with cancer. Biologicals. Jun 2006;34(2):109-112.
25. Aycock WL. The significance of the age distribution of poliomyelitis: evidence of transmission through contact. Am J Hyg. 1928;8:35-54.
26. Baboonian C, Davies MJ, Booth JC, McKenna WJ. Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol. 1997;223:31-52.
27. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997;78(6):539-543.
28. Barral PM, Morrison JM, Drahos J, et al. MDA-5 is cleaved in poliovirus-infected cells. J Virol. 2007;81(8):3677-3684.
29. Bell EJ, McCartney RA. A study of Coxsackie B virus infections, 1972-1983. J Hyg. 1984;93(2):197-203.
30. Bell EJ, McCartney RA, Basquill D, Chaudhuri AK. Mu-antibody capture ELISA for the rapid diagnosis of enterovirus infections in patients with aseptic meningitis. J Med Virol. 1986;19(3):213-217.
31. Bendig JWA, O'Brien PS, Muir P, Porter HJ, Caul EO. Enterovirus sequences resembling coxsackievirus A2 detected in stool and spleen from a girl with fatal myocarditis. J.Med.Virol. 2001;64:482-486.
32. Benschop KSM, Schinkel J, Minnaar RP, et al. Human parechovirus infections in Dutch children and the association between serotype and disease severity. Clin Infect Dis. 2006;42:204-210.
33. Berlin BS, Simon NM, Bovner RN. Myoglobinuria precipitated by viral infection. JAMA. 1974;227(12):1414-1415.
34. Birmingham ME, Aylward RB, Cochi SL, Hull HF. National immunization days: state of the art. J Infect Dis. 1997;175(Suppl 1):S183-188.
35. Birmingham ME, Linkins RW, Hull BP, Hull HF. Poliomyelitis surveillance: the compass for eradication. J Infect Dis. 1997;175(Suppl 1):S146-S150.
36. Bodian D. Emerging concept of poliomyelitis infection. Science. 1955;122(3159):105-108.
37. Bodian D. Histopathologic basis of clinical findings in poliomyelitis. Am J Med. May 1949;6(5):563-578.
38. Bodian D. Viremia in experimental poliomyelitis. II. Viremia and the mechanism of the provoking effect of injections or trauma. Am J Hyg. 1954;60(3):358-370.
39. Bodian D, Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses. III. The grouping of fourteen strains into three basic immunological types. Am J Hyg. 1949;49:234-245.
40. Boettler T, von HM. Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Rev Clin Immunol. 2011;7(1):45-53.
41. Boivin G, Abed Y, Boucher FD. Human parechovirus 3 and neonatal infections. Emerg Infect Dis. Jan 2005;11(1):103-105.
42. Boman J, Nilsson B, Juto P. Serum IgA, IgG, and IgM responses to different enteroviruses as measured by a coxsackie B5-based indirect ELISA. J Med Virol. 1992;38(1):32-35.
43. Bothig B, Danes L, Dittmann S. Immunogenicity of oral poliomyelitis vaccine (OPV) against variants of wild poliovirus type 3. Bull World Health Organ 1990;68(5):597-600.
44. Bowles NE, Dubowitz V, Sewry CA, Archard LC. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet. 1987;1(8540):1004-1007.
45. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;1:1120-1123.
46. Brown B, Oberste MS, Maher K, Pallansch MA. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J Virol. Aug 2003;77(16):8973-8984.
47. Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. 1999;73(12):9969-9975.
48. Buisman AM, Abbink F, Schepp RM, Sonsma JA, Herremans T, Kimman TG. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J. Infect. Dis. 2008;197(5):698-706.
49. Burnet FM. Poliomyelitis in the light of recent experimental work. Health Bull 1945;(81-82):2173-2177.
50. Byington CL, Taggart EW, Carroll KC, Hillyard DR. A polymerase chain reaction-based epidemiologic investigation of the incidence of nonpolio enteroviral infections in febrile and afebrile infants 90 days and younger. Pediatrics. 1999;103(3):E27.
51. Caggana M, Chan P, Ramsingh A. Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype. J Virol. 1993;67(8):4797-4803.
52. Carson SD, Chapman NM, Hafenstein S, et al. Variation of coxsackievirus B3 capsid primary structure, ligands, and stability are selected in a coxsackievirus and adenovirus receptor-limited environment. J Virol 2011;85:3306-3314.
53. Carson SD, Kim KS, Pirruccello SJ, Tracy S, Chapman NM. Endogenous low-level expression of the coxsackievirus and adenovirus receptor enables coxsackievirus B3 infection of RD cells. Journal of General Virology. 2007;88(Pt 11):3031-3038.
54. Cashman NR, Maselli R, Wollmann RL, Roos R, Simon R, Antel JP. Late denervation in patients with antecedent paralytic poliomyelitis. New England Journal of Medicine. 1987;317(1):7-12.
55. Centers for Disease Control and Prevention. National laboratory inventory for global poliovirus containment-United States, November 2003. MMWR - Morbidity & Mortality Weekly Report. 2004;53(21):457-459.
56. Centers for Disease Control and Prevention. Notes from the field: poliomyelitis outbreak-Republic of the Congo, September 2010-February 2011. MMWR Morb Mortal Wkly Rep. 2011;60(10):312-313.
57. Centers for Disease Control and Prevention. Outbreak of polio in adults-Namibia, 2006. MMWR Morb Mortal Wkly Rep. Nov 10 2006;55(44):1198-1201.
58. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission - worldwide, January 2011-March 2012. Morbidity & Mortality Weekly Report. 2012;61(19):353-357.
59. Centers for Disease Control and Prevention. Tracking progress toward global polio eradication, 2010-2011. Morbidity & Mortality Weekly Report. 2012;61:265-269.
60. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, July 2009-March 2011. Morbidity & Mortality Weekly Report. 2011;60(25):846-850.
61. Cetta F, Michels VV. The autoimmune basis of dilated cardiomyopathy. Ann Med. Apr 1995;27(2):169-173.
62. Chambon M, Bailly JL, Peigue-Lafeuille H. Comparative sensitivity of the echovirus type 25 JV-4 prototype strain and two recent isolates to glutaraldehyde at low concentrations. Appl Environ Microbiol. 1994;60(2):387-392.
63. Chapman NM, Kim KS, Drescher KM, Oka K, Tracy S. 5' terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology. 2008;375(2):480-491.
64. Chapman NM, Romero JR, Pallansch MA, Tracy S. Sites other than nucleotide 234 determine cardiovirulence in natural isolates of coxsackievirus B3. J.Med.Virol. 1997;52(3):258-261.
65. Charcot JM, Joffroy A. Cas de paralysie infantile spinale avec lesins des cornes anterieures de la substance grise de la moelle epiniere. Arch Physiol Norm Pathol. 1870;3:134-152.
66. Chen HL, Huang JY, Chu TW, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008;26(23):2882-2889.
67. Chen SX, Mei SW, Bao SH, et al. Immunological status and pathology of coxsackie B viral myocarditis and dilated cardiomyopathy. Chin Med J (Engl). 1993;106:659-664.
68. Chiou CC, Liu WT, Chen SJ, et al. Coxsackievirus B1 infection in infants less than 2 months of age. American Journal of Perinatology. 1998;15(3):155-159.
69. Chonmaitree T, Ford C, Sanders C, Lucia HL. Comparison of cell cultures for rapid isolation of enteroviruses. J Clin Microbiol. 1988;26(12):2576-2580.
70. Chonmaitree T, Mann L. Respiratory infections. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: ASM Press; 1995:255-270.
71. Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Laboratory Investigation. 1992;66(1):24-31.
72. Chumakov M, Voroshilova M, Shindarov L, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60(3-4):329-340.
73. Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855-1862.
74. Clark CS, Bjornson AB, Schiff GM, Phair JP, Van Meer GL, Gartside PS. Sewage worker's syndrome [letter]. Lancet. 1977;1(8019):1009.
75. Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes. Lancet. 1995;346(8969):221-223.
76. Cochi SL, Sutter RW, Aylward RB. Possible global strategies for stopping polio vaccination and how they could be harmonized. Dev Biol (Basel). 2001;105:153-158; discussion 159.
77. Codd MB, Sugrue DD, Gersh BJ, Melton LJ, 3rd. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. Sep 1989;80(3):564-572.
78. Colbere-Garapin F, Duncan G, Pavio N, Pelletier I, Petit I. An approach to understanding the mechanisms of poliovirus persistence in infected cells of neural or non-neural origin. Clin Diagn Virol. 1998;9(2-3):107-113.
79. Conyn-Van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T. Immunity to poliomyelitis in the Netherlands. American Journal of Epidemiology. Feb 1 2001;153(3):207-214.
80. Cooney MK, Hall CE, Fox JP. The Seattle virus watch. 3. Evaluation of isolation methods and summary of infections detected by virus isolations. American Journal of Epidemiology. 1972;96(4):286-305.
81. Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Horodniceanu F. Natural variation of poliovirus neutralization epitopes. Infection & Immunity. 1983;41(3):1217-1225.
82. Crotty S, Hix L, Sigal LJ, Andino R. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. Journal of General Virology. 2002;83(Pt 7):1707-1720.
83. Crowder S, Kirkegaard K. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nat Genet. Jul 2005;37(7):701-709.
84. D'Alessio DJ. A case-control study of group B Coxsackievirus immunoglobulin M antibody prevalence and HLA-DR antigens in newly diagnosed cases of insulin-dependent diabetes mellitus. American Journal of Epidemiology. 1992;135(12):1331-1338.
85. Dagan R, Hall CB, Powell KR, Menegus MA. Epidemiology and laboratory diagnosis of infection with viral and bacterial pathogens in infants hospitalized for suspected sepsis. J Pediatr. 1989;115(3):351-356.
86. Dagan R, Menegus M. Nonpolio enteroviruses and the febrile infant. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: ASM Press; 1995:239-254.
87. Dalakas MC. Enteroviruses and human neuromuscular diseases. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: ASM Press; 1995:387-398.
88. Dales S, Eggers HJ, Tamm I, Palade GE. Electron microscopic study of the formation of poliovirus. Virology. 1965;26:379-389.
89. Dalldorf G, Sickles GM. An unidentified, filtrible agent isolated from the feces of children with paralysis. Science. 1948;108:61-62.
90. Day C, Cumming H, Walker J. Enterovirus-specific IgM in the diagnosis of meningitis. Journal of Infection. 1989;19(3):219-228.
91. de Jong AS, de Mattia F, van Dommelen MM, et al. Functional analysis of picornavirus 2B proteins: effects on calcium homeostasis and intracellular protein trafficking. Journal of Virology. 2008;82(7):3782-3790.
92. de Leeuw N, Melchers WJ, Balk AH, de Jonge N, Galama JM. No evidence for persistent enterovirus infection in patients with end-stage idiopathic dilated cardiomyopathy. J Infect Dis. 1998;178(1):256-259.
93. de Quadros CA, Andrus JK, Olive JM, Carrasco P. Strategies for poliomyelitis eradication in developing countries. Public Health Reviews. 1993;21(1-2):65-81.
94. Dechkum N, Pangsawan Y, Jayavasu C, Saguanwongse S. Coxsackie B virus infection and myopericarditis in Thailand, 1987-1989. Southeast Asian Journal of Tropical Medicine & Public Health. 1998;29(2):273-276.
95. Deibel R, Gross LL, Collins DN. Isolation of a new enterovirus (38506). Proceedings of the Society for Experimental Biology & Medicine. 1975;148(1):203-207.
96. Dery P, Marks MI, Shapera R. Clinical manifestations of coxsackievirus infections in children. American Journal of Diseases of Children. 1974;128(4):464-468.
97. Destombes J, Couderc T, Thiesson D, Girard S, Wilt SG, Blondel B. Persistent poliovirus infection in mouse motoneurons. J Virol. Feb 1997;71(2):1621-1628.
98. Diana GD, Pevear DC. Antipicornavirus drugs: current status. Antiviral Chemistry & Chemotherapy. 1997;8:401-408.
99. Dorval BL, Chow M, Klibanov AM. Stabilization of poliovirus against heat inactivation. Biochemical & Biophysical Research Communications. 1989;159(3):1177-1183.
100. Douglas JD, Soike KF, Raynor J. The incidence of poliovirus in chimpanzees (Pan troglodytes). Laboratory Animal Care. 1970;20(2):265-268.
101. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis. 1997;175(Suppl 1):S286-S292.
102. Drebot MA, Campbell JJ, Lee SH. A genotypic characterization of enteroviral antigenic variants isolated in eastern Canada. Virus Res. 1999;59(2):131-140.
103. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. Risk Analysis. 2008;28:855-876.
104. Dunn JJ, Bradrick SS, Chapman NM, Tracy SM, Romero JR. The stem loop II within the 5' nontranslated region of clinical coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model. J. Infect. Dis. 2003;187(10):1552-1561.
105. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949;109:85-87.
106. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol. 2008;3:127-155.
107. Estívariz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis. 2008;197(3):347-354.
108. Estrin M, Smith C, Huber SA. Coxsackievirus B-3 myocarditis. T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment. American Journal of Pathology. 1986;125:244-251.
109. Evans DM, Dunn G, Minor PD, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985;314:548-550.
110. Fairweather D, Yusung S, Frisancho S, et al. IL-12 receptor á1 and Toll-like receptor 4 increase IL-1á- and IL-18-associated myocarditis and coxsackievirus replication. Journal of Immunology. 2003;170(9):4731-4737.
111. Feachem R, Garelick H, Slade J. Enteroviruses in the environment. Tropical Diseases Bulletin. 1981;78(3):185-230.
112. Feuer R, Mena I, Pagarigan RR, Harkins S, Hassett DE, Whitton JL. Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. Am J Pathol. Oct 2003;163(4):1379-1393.
113. Feuer R, Mena I, Pagarigan RR, Hassett DE, Whitton JL. Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence / latency. Medical Microbiology and Immunology (Berlin). 2004;193(2/3):83-90.
114. Feuer R, Mena I, Pagarigan RR, Slifka MK, Whitton JL. Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro Journal of Virology. 2002;76(9):4430-4440.
115. Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. Sep 2007;9(11):1299-1306.
116. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. Apr 2007;125(1):61-68.
117. Foo DG, MacAry PA, Alonso S, Poh CL. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunology. 2008;21(2):215-224.
118. Freistadt MS, Kaplan G, Racaniello VR. Heterogeneous expression of poliovirus receptor-related proteins in human cells and tissues. Mol. Cell Biol. 1990;10(11):5700-5706.
119. Frisancho-Kiss S, Davis SE, Nyland JF, et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. Journal of Immunology. 2007;178(11):6710-6714.
120. Frisk G, Lindberg MA, Diderholm H. Persistence of coxsackievirus B4 infection in rhabdomyosarcoma cells for 30 months. Brief report. Archives of Virology. 1999;144(11):2239-2245.
121. Frisk G, Nilsson E, Ehrnst A, Diderholm H. Enterovirus IgM detection: specificity of mu-antibody-capture radioimmunoassays using virions and procapsids of Coxsackie B virus. J Virol Meth. 1989;24(1-2):191-202.
122. Gauntt CJ, Arizpe HM, Higdon AL, et al. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. Journal of Immunology. 1995;154:2983-2995.
123. Gauntt CJ, Higdon AL, Arizpe HM, et al. Epitopes shared between coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis. Clin Immunol Immunopathol. 1993;68:129-134.
124. Gelfand HM, Holguin AH, Marchetti GE, Feorino PM. A continuing surveillance of enterovirus infections in healthy children in six United States cities. I. Viruses isolated during 1960 and 1961. Am J Hyg. Nov 1963;78:358-375.
125. Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bulletin of the World Health Organization. 1994;72(6):973-983.
126. Girard S, Couderc T, Destombes J, Thiesson D, Delpeyroux F, Blondel B. Poliovirus induces apoptosis in the mouse central nervous system. J Virol. Jul 1999;73(7):6066-6072.
127. Girard S, Gosselin AS, Pelletier I, Colbere-Garapin F, Couderc T, Blondel B. Restriction of poliovirus RNA replication in persistently infected nerve cells. Journal of General Virology. 2002;83(Pt 5):1087-1093.
128. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proceedings of the National Academy of Sciences, U.S.A. 2006;103(22):8459-8464.
129. Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol. Jan 2005;79(2):1027-1035.
130. Godeny EK, Gauntt CJ. In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis. American Journal of Pathology. 1987;129:267-276.
131. Goldwater PN. Immunoglobulin M capture immunoassay in investigation of coxsackievirus B5 and B6 outbreaks in South Australia. J Clin Microbiol. 1995;33(6):1628-1631.
132. Gomez RM, Lopez Costa JJ, Pecci Saavedra G, Berria MI. Ultrastructural study of cell injury induced by coxsackievirus B3 in pancreatic and cardiac tissues. Medicina.(B.Aires). 1993;53:300-306.
133. Gondo K, Kusuhara K, Take H, Ueda K. Echovirus type 9 epidemic in Kagoshima, southern Japan: seroepidemiology and clinical observation of aseptic meningitis. Pediatr Infect Dis J. 1995;14(9):787-791.
134. Gorgievski-Hrisoho M, Schumacher JD, Vilimonovic N, Germann D, Matter L. Detection by PCR of enteroviruses in cerebrospinal fluid during a summer outbreak of aseptic meningitis in Switzerland. J Clin Microbiol. 1998;36(9):2408-2412.
135. Goyal SM, Gerba CP. Comparative adsorption of human enteroviruses, simian rotavirus, and selected bacteriophages to soils. Appl Environ Microbiol. 1979;38(2):241-247.
136. Grandien M, Forsgren M, Ehrnst A. Enteroviruses and Reoviruses. In: Lennette EH, Schmidt NJ, eds. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 6th ed. Washington, DC: American Public Health Association; 1989:513-569.
137. Gravanis MB, Sternby NH. Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med. Apr 1991;115(4):390-392.
138. Grist NR, Bell EJ, Assaad F. Enteroviruses in human disease. Prog Med Virol. 1978;24:114-157.
139. Groarke JM, Pevear DC. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J Infect Dis. Jun 1999;179(6):1538-1541.
140. Gromeier M, Wimmer E. Mechanism of injury-provoked poliomyelitis. J Virol. 1998;72(6):5056-5060.
141. Guo R, Tang EH, Wang H, et al. Preliminary studies on antigenic variation of poliovirus using neutralizing monoclonal antibodies. J Gen Virol. 1987;68(Pt 4):989-994.
142. Haarmann CM, Schwimmbeck PL, Mertens T, Schultheiss HP, Strauer BE. Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides. Virology May 1 1994;200(2):381-389.
143. Halim S, Ramsingh AI. A point mutation in VP1 of coxsackievirus B4 alters antigenicity. Virology. 2000;269(1):86-94.
144. Halim SS, Collins DN, Ramsingh AI. A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy. AIDS Res Hum Retroviruses. 2000;16(15):1551-1558.
145. Halim SS, Ostrowski SE, Lee WT, Ramsingh AI. Immunogenicity of a foreign peptide expressed within a capsid protein of an attenuated coxsackievirus. Vaccine. 2001;19(7-8):958-965.
146. Hall CE, Cooney MK, Fox JP. The Seattle virus watch program. I. Infection and illness experience of virus watch families during a communitywide epidemic of echovirus type 30 aseptic meningitis. American Journal of Public Health & the Nations Health. 1970;60(8):1456-1465.
147. Haller AA, Stewart SR, Semler BL. Attenuation stem-loop lesions in the 5' noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J Virol. 1996;70(3):1467-1474.
148. Halsey NA, Pinto J, Rosales F, et al. Search for poliovirus carriers in persons with primary immune deficiency diseases in the United States, Mexico and Brazil. Bull World Health Organ 2004;82:3-8.
149. Hartig PC, Webb SR. Coxsackievirus B4 heterogeneity: effect of passage on neutralization and mortality. Acta Virologica. 1986;30(6):475-486.
150. Harvala H, Sharp CP, Ngole EM, Delaporte E, Peeters M, Simmonds P. Detection and genetic characterization of enteroviruses circulating among wild populations of chimpanzees in Cameroon; relationship with human and simian enteroviruses. J Virol. 2011;85:4480-4486.
151. Hashimoto I, Komatsu T. Myocardial changes after infection with Coxsackie virus B3 in nude mice. Br.J.Exp.Pathol. 1978;59(1):13-20.
152. Heck CF, Shumway SJ, Kaye MP. The Registry of the International Society for Heart Transplantation: sixth official report-1989. J Heart Transplant. 1989;8:271-276.
153. Heim A, Canu A, Kirschner P, et al. Synergistic interaction of interferon-á and interferon-g in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts J Infect Dis. 1992;166:958-965.
154. Heine J. Beobachtungen uber Lahmungszustande der untern Extermitaten und deren Behandlung. Stuttgart: Kohler; 1840.
155. Heinz BA, Rueckert RR, Shepard DA, et al. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol. 1989;63(6):2476-2485.
156. Heinz BA, Vance LM. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol. 1996;70(7):4854-4857.
157. Henke A, Huber SA, Stelzner A, Whitton JL. The role of CD8 + T lymphocytes in coxsackievirus B3-induced myocarditis. Journal of Virology. 1995;69(11):6720-6728.
158. Hennessey KA, Lago H, Diomande F, et al. Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire. J Infect Dis. Dec 15 2005;192(12):2124-2128.
159. Herzum M, Huber SA, Weller R, Grebe R, Maisch B. Treatment of experimental murine Coxsackie B3 myocarditis. Eur Heart J. 1991;12(Suppl D):200-202.
160. Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature. Apr 7 2005;434(7034):699-700.
161. Hilfenhaus J, Nowak T. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate. Vox Sanguinis. 1994;67(Suppl 1):62-66.
162. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. New England Journal of Medicine. 1999;341(13):929-935.
163. Hodgson J, Bendig J, Keeling P, Booth JC. Comparison of two immunoassay procedures for detecting enterovirus IgM. J Med Virol. 1995;47(1):29-34.
164. Hofschneider PH, Klingel K, Kandolf R. Toward understanding the pathogenesis of enterovirus-induced cardiomyopathy: molecular and ultrastructural approaches. J Struct Biol. 1990;104:32-37.
165. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229(4720):1358-1365.
166. Hogle JM, Filman DJ. The antigenic structure of poliovirus. Philosophical Transactions of the Royal Society of London - Series B: Biological Sciences. 1989;323(1217):467-478.
167. Hohenadl C, Klingel K, Mertsching J, Hofschneider PH, Kandolf R. Strand-specific detection of enteroviral RNA in myocardial tissue by in situ hybridization. Molecular & Cellular Probes. 1991;5(1):11-20.
168. Holtz LR, Finkbeiner SR, Zhao G, et al. Klassevirus 1, a previously undescribed member of the family Picornaviridae, is globally widespread. Virol J. 2009;6:86.
169. Honig EI, Melnick JL, Isacson P, Parr R, Myers IL, Walton M. An endemiological study of enteric virus infections: poliomyelitis, coxsackie, and orphan (ECHO) viruses isolated from normal children in two socioeconomic groups. J Exp Med. Feb 1 1956;103(2):247-262.
170. Horstmann DM. Enterovirus infections of the central nervous system. The present and future of poliomyelitis. Medical Clinics of North America. 1967;51(3):681-692.
171. Horstmann DM. Poliomyelitis: severity and type of disease in different age groups. Ann NY Acad Sci. 1955;61:956-967.
172. Hovi T, Stenvik M. Selective isolation of poliovirus in recombinant murine cell line expressing the human poliovirus receptor gene. J Clin Microbiol. 1994;32(5):1366-1368.
173. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. New England Journal of Medicine. 1999;341(13):936-942.
174. Huang SC, Chang CL, Wang PS, Tsai Y, Liu HS. Enterovirus 71-induced autophagy detected in vitro and in vivo promotes viral replication. J. Med.Virol. 2009;81(7):1241-1252.
175. Huber S, Sartini D. T cells expressing the V g 1 T-cell receptor enhance virus-neutralizing antibody response during coxsackievirus B3 infection of BALB/c mice: differences in male and female mice. Viral Immunology. 2005;18(4):730-739.
176. Huber S, Song WC, Sartini D. Decay-accelerating factor (CD55) promotes CD1d expression and Vgamma4+ T-cell activation in coxsackievirus B3-induced myocarditis. Viral Immunology. 2006;19(2):156-166.
177. Huber SA. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity. Feb 2006;39(1):55-61.
178. Huber SA. Autoimmunity in myocarditis: relevance of animal models. Clin Immunol Immunopathol. 1997;83(2):93-102.
179. Huber SA, Born W, O'Brien R. Dual functions of murine gammadelta cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vgamma1+ and Vgamma4+ cells. Microbes Infect. 2005;7(3):537-543.
180. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. American Journal of Pathology. 1984;116:21-29.
181. Huber SA, Lyden DC, Lodge PA. Immunopathogenesis of experimental Coxsackievirus induced myocarditis: role of autoimmunity. Herz. 1985;10:1-7.
182. Huber SA, Moraska A, Cunningham M. Alterations in major histocompatibility complex association of myocarditis induced by coxsackievirus B3 mutants selected with monoclonal antibodies to group A streptococci. Proc Natl Acad Sci U.S.A. 1994;91(12):5543-5547.
183. Huhn MH, Hultcrantz M, Lind K, Ljunggren HG, Malmberg KJ, Flodstrom-Tullberg M. IFN-g production dominates the early human natural killer cell response to Coxsackievirus infection. Cellular Microbiology. 2008;10(2):426-436.
184. Huhn MH, McCartney SA, Lind K, Svedin E, Colonna M, Flodstrom-Tullberg M. Melanoma differentiation-associated protein-5 (MDA-5) limits early viral replication but is not essential for the induction of type 1 interferons after Coxsackievirus infection. Virology. 2010;401(1):42-48.
185. Hull BP, Dowdle WR. Poliovirus surveillance: building the global Polio Laboratory Network. J Infect Dis. 1997;175(Suppl 1):S113-S116.
186. Hull HF, Ward NA, Hull BP, Milstien JB, de Quadros C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994;343(8909):1331-1337.
187. Huovilainen A, Kinnunen L, Ferguson M, Hovi T. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak. J Gen Virol. 1988;69(Pt 8):1941-1948.
188. Hyöty H, Hiltunen M, Lonnrot M. Enterovirus infections and insulin dependent diabetes mellitus-evidence for causality. Clinical & Diagnostic Virology. 1998;9(2-3):77-84.
189. Hyypiä T, Hovi T, Knowles NJ, Stanway G. Classification of enteroviruses based on molecular and biological properties. J Gen Virol. 1997;78(Pt 1):1-11.
190. Ida-Hosonuma M, Iwasaki T, Taya C, et al. Comparison of neuropathogenicity of poliovirus in two transgenic mouse strains expressing human poliovirus receptor with different distribution patterns. Journal of General Virology. 2002;83(Pt 5):1095-1105.
191. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. Journal of Virology. 2005;79(7):4460-4469.
192. Irvine DH, Irvine AB, Gardner PS. Outbreak of E.C.H.O. virus type 30 in a general practice. Brit Med J. 1967;4(582):774-776.
193. Ito M, Yamashita T, Tsuzuki H, Takeda N, Sakae K. Isolation and identification of a novel human parechovirus. J Gen Virol. 2004;85:391-398.
194. Jackson WT, Giddings TH Jr, Taylor MP, et al. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biology. 2005;3(5):e156.
195. Jankovic B, Pasic S, Kanjuh B, et al. Severe neonatal echovirus 17 infection during a nursery outbreak. Pediatr Infect Dis J. 1999;18(4):393-394.
196. Jarasch N, Martin U, Zell R, Wutzler P, Henke A. Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19 + B lymphocytes. Apoptosis. 2007;12(9):1633-1643.
197. Jenista JA, Powell KR, Menegus MA. Epidemiology of neonatal enterovirus infection. J Pediatr. 1984;104(5):685-690.
198. Johnson R. Viral Infections of the Nervous System. 2nd ed. Philadelphia: JB Lippincott-Raven; 1998.
199. Joki-Korpela P, Hyypia T. Diagnosis and epidemiology of echovirus 22 infections. Clin Infect Dis. 1998;27(1):129-136.
200. Jones MJU, Kolb M, Votava HJ, Johnson RL, Smith TF. Case reports. Intrauterine echovirus type II infection. Mayo Clinic Proceedings. 1980;55(8):509-512.
201. Jubelt B, Gallez-Hawkins G, Narayan O, Johnson RT. Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies. Journal of Neuropathology & Experimental Neurology. 1980;39(2):138-148.
202. Jubelt B, Salazar-Grueso EF, Roos RP, Cashman NR. Antibody titer to the poliovirus in blood and cerebrospinal fluid of patients with post-polio syndrome. Ann NY Acad Sci. 1995;753:201-207.
203. Juhela S, Hyoty H, Lonnrot M, Roivainen M, Simell O, Ilonen J. Enterovirus infections and enterovirus specific T-cell responses in infancy. J. Med. Virol. 1998;54(3):226-232.
204. Kallewaard NL, Zhang L, Chen JW, Guttenberg M, Sanchez MD, Bergelson JM. Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis. Cell Host & Microbe. 2009;6(1):91-98.
205. Kanamitsu M, Kasamaki A, Ogawa M, Kasahara S, Imamura M. Immunofluorescent study on the pathogenesis of oral infection of poliovirus in monkeys. Jpn J Med Sci Biol. 1967;20(2):175-194.
206. Kandolf R. Molecular biology of viral heart disease. Herz. 1993;18(4):238-244.
207. Kandolf R, Canu A, Hofschneider PH. Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J. Mol.Cell Cardiol. 1985;17:167-181.
208. Kandolf R, Sauter M, Aepinus C, Schnorr JJ, Selinka HC, Klingel K. Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res. 1999;62(2):149-158.
209. Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection. Nature Reviews Immunology. 2010;10(10):688-698.
210. Kaplan MH, Klein SW, McPhee J, Harper RG. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Reviews of Infectious Diseases. 1983;5(6):1019-1032.
211. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. May 4 2006;441(7089):101-105.
212. Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004;113(12):1743-1753.
213. Kawamura N, Kohara M, Abe S, et al. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989;63(3):1302-1309.
214. Kaye SB, Morton CE, Tong CY, O'Donnell NP. Echovirus keratoconjunctivitis. American Journal of Ophthalmology. 1998;125(2):187-190.
215. Kemball CC, Harkins S, Whitton JL. Enumeration and functional evaluation of virus-specific CD4+ and CD8+ T cells in lymphoid and peripheral sites of coxsackievirus B3 infection. J Virol. 2008;82:4331-4342.
216. Kessler HH, Santner B, Rabenau H, et al. Rapid diagnosis of enterovirus infection by a new one-step reverse transcription-PCR assay. J Clin Microbiol. 1997;35(4):976-977.
217. Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Pallansch MA. Molecular epidemiology of polioviruses. Seminars in Virology. 1995;6:401-414.
218. Kew OM, Nottay BK. Molecular epidemiology of polioviruses. Reviews of Infectious Diseases. 1984;6(Suppl 2):S499-504.
219. Kew OM, Nottay BK, Rico-Hesse R, Pallansch MA. Molecular epidemiology of wild poliovirus transmission. In: Kurstak E, Marusyk RG, Murphy FA, van Regenmortel MHV, eds. Virus variability, epidemiology, and control. Vol 2. New York: Plenum Medical Book Company; 1990:199-222.
220. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635.
221. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36(10):2893-2899.
222. Kew OM, Wright P, Agol V, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ. 2004;82:16-23.
223. Khetsuriani N, LaMonte A, Oberste MS, Pallansch MA. Enterovirus surveillance - United States, 1970-2005. MMWR Surv Summ. 2006;55(SS-8):1-20.
224. Khetsuriani N, Prevots R, Quick L, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188:1845-1852.
225. Kilpatrick DR, Nottay B, Yang CF, et al. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol. 1998;36(2):352-357.
226. Kilpatrick DR, Nottay B, Yang CF, et al. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy. J Clin Microbiol. 1996;34(12):2990-2996.
227. Kim KS, Chapman NM, Tracy S. Replication of coxsackievirus B3 in primary cell cultures generates novel viral genome deletions. Journal of Virology. 2008;82(4):2033-2037.
228. Kim KS, Tracy S, Tapprich W, et al. 5'-Terminal deletions occur in Coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. Journal of Virology. 2005;79(11):7024-7041.
229. Kitamura N, Semler BL, Rothberg PG, et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291(5816):547-553.
230. Klingel K, Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl. 1993;88:79-85.
231. Klingel K, Stephan S, Sauter M, et al. Pathogenesis of murine enterovirus myocarditis: Virus dissemination and immune cell targets. Journal of Virology. 1996;70:8888-8895.
232. Knowles NJ, Hovi T, Hyypiä T, et al. Picornaviridae. In: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ, eds. Virus taxonomy: classification and nomenclature of viruses: Ninth Report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier; 2011:855-880.
233. Kogon A, Spigland I, Frothingham TE, et al. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VII. Observations on viral excretion, seroimmunity, intrafamilial spread and illness association in coxsackie and echovirus infections. American Journal of Epidemiology. 1969;89(1):51-61.
234. Koide H, Kitaura Y, Deguchi H, Ukimura A, Kawamura K, Hirai K. Genomic detection of enteroviruses in the myocardium-studies on animal hearts with coxsackievirus B3 myocarditis and endomyocardial biopsies from patients with myocarditis and dilated cardiomyopathy. Jpn. Circ. J. 1992;56(10):1081-1093.
235. Koike K, Masumoto N, Kasahara K, et al. Tumor necrosis factor-alpha stimulates prolactin release from anterior pituitary cells: a possible involvement of intracellular calcium mobilization. Endocrinology. 1991;128(6):2785-2790.
236. Koike S, Taya C, Kurata T, et al. Transgenic mice susceptible to poliovirus. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(3):951-955.
237. Komatsu H, Shimizu Y, Takeuchi Y, Ishiko H, Takada H. Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatric Neurology. 1999;20(1):17-23.
238. Kono R. Apollo 11 disease or acute hemorrhagic conjunctivitis: a pandemic of a new enterovirus infection of the eyes. American Journal of Epidemiology. 1975;101(5):383-390.
239. Kopecka H, Brown B, Pallansch M. Genotypic variation in coxsackievirus B5 isolates from three different outbreaks in the United States. Virus Res. 1995;38(2-3):125-136.
240. Kramer M, Schulte BM, Toonen LW, et al. Phagocytosis of picornavirus-infected cells induces an RNA-dependent antiviral state in human dendritic cells. Journal of Virology. 2008;82(6):2930-2937.
241. Kramer M, Schulte BM, Toonen LW, et al. Echovirus infection causes rapid loss-of-function and cell death in human dendritic cells. Cellular Microbiology. 2007;9(6):1507-1518.
242. Labadie K, Pelletier I, Saulnier A, Martin J, Colbere-Garapin F. Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology. Jan 5 2004;318(1):66-78.
243. Landsteiner K, Popper E. Mikroskopische Praparate von einem Menschlichen und zwei Affenruckenmarken. Wien Klinische Wochenschrift. 1908;21:1830.
244. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. LPS promotes CB3-induced myocarditis in resistant B10.A mice. Cell Immunol. 1991;136(1):219-233.
245. Langford MP, Kadi RM, Ganley JP, Yin-Murphy M. Inhibition of epidemic isolates of coxsackievirus type A 24 by recombinant and natural interferon alpha and interferon beta. Intervirology. 1988;29(6):320-327.
246. Leake JP. Poliomyelitis following vaccination against this disease. Journal of the American Medical Association. 1935;105(26):2152-2153.
247. Leff RL, Love LA, Miller FW, et al. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet. 1992;339(8803):1192-1195.
248. Leipner C, Borchers M, Merkle I, Stelzner A. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice. J Hum Virol. 1999;2(2):102-114.
249. Leon-Monzon M, Dalakas MC. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. Annals of Neurology. 1992;32(2):219-222.
250. Leon-Monzon ME, Dalakas MC. Detection of poliovirus antibodies and poliovirus genome in patients with the post-polio syndrome. Ann NY Acad Sci. 1995;753:208-218.
251. Leparc-Goffart I, Julien J, Fuchs F, Janatova I, Aymard M, Kopecka H. Evidence of presence of poliovirus genomic sequences in cerebrospinal fluid from patients with postpolio syndrome [see comments]. J Clin Microbiol. 1996;34(8):2023-2026.
252. Li L, Victoria J, Kapoor A, et al. A novel picornavirus associated with gastroenteritis. J Virol. 2009;83(22):12002-12006.
253. Liljeqvist JA, Bergstrom T, Holmstrom S, et al. Failure to demonstrate enterovirus aetiology in Swedish patients with dilated cardiomyopathy. J Med Virol. 1993;39(1):6-10.
254. Lim KH, Yin-Murphy M. An epidemic of conjunctivitis in Singapore in 1970. Singapore Med J. Oct 1971;12(5):247-249.
255. Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, Chen SH. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. Journal of Virology. 2009;83(13):6477-6483.
256. Lipskaya G, Chervonskaya EA, Belova GI, et al. Geographical genotypes (geotypes) of poliovirus case isolates from the former Soviet Union: relatedness to other known poliovirus genotypes. J Gen Virol. 1995;76(Pt 7):1687-1699.
257. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Pallansch MA, Kew OM. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J Virol. 2000;74:11153-11161.
258. Lodge PA, Herzum M, Olszewski J, Huber SA. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. American Journal of Pathology. 1987;128(3):455-463.
259. Loo YM, Fornek J, Crochet N, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. Journal of Virology. 2008;82(1):335-345.
260. Lum LCS, Wong KT, Lam SK, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133(6):795-798.
261. Ma JF, Straub TM, Pepper IL, Gerba CP. Cell culture and PCR determination of poliovirus inactivation by disinfectants. Appl Environ Microbiol. 1994;60(11):4203-4206.
262. Macadam AJ, Pollard SR, Ferguson G, et al. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology. 1991;181(2):451-458.
263. Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology. 1993;192(1):18-26.
264. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004;363:1509-1513.
265. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113(6):876-890.
266. Magnius LO, Saleh LH, Vikerfors T, Norder H. A solid-phase reverse immunosorbent test for the detection of enterovirus IgM. J Virol Meth. 1988;20(1):73-82.
267. Mahfoud F, Gartner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32:897-903.
268. Mahon BP, Katrak K, Nomoto A, Macadam AJ, Minor PD, Mills KH. Poliovirus-specific CD4 + Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. Journal of Experimental Medicine. 1995;181(4):1285-1292.
269. Marchant D, Si X, Luo H, McManus B, Yang D. The impact of CVB3 infection on host cell biology. Current Topics in Microbiology and Immunology. 2008;323:177-198.
270. Martin J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. Journal of Virology. 2000;74(7):3001-3010.
271. Martino TA, Liu PP, Petric M, Sole MJ. Enteroviral myocarditis and cardiomyopathy: a review of clinical and experimental studies. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: ASM Press; 1995:291-351.
272. Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M. Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. Journal of Virology. 1985;56(2):651-654.
273. McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Reviews of Infectious Diseases. 1987;9(2):334-356.
274. Medin O. Ueber eine Epidemie von spinaler Kinkerlahmung. Verh X Int Med Kongr1891.
275. Melchers W, de Visser M, Jongen P, et al. The postpolio syndrome: no evidence for poliovirus persistence [see comments]. Annals of Neurology. 1992;32(6):728-732.
276. Melnick JL. Current status of poliovirus infections. Clinical Microbiology Reviews. 1996;9(3):293-300.
277. Melnick JL. Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Reviews of Infectious Diseases. 1984;6(Suppl 2):S387-S390.
278. Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996:655-712.
279. Melnick JL, Shaw EW, Curnen EC. A virus isolated from patients diagnosed as non-paralytic poliomyelitis or aseptic meningitis. Proceedings of the Society for Experimental Biology and Medicine. 1949;71:344-349.
280. Mena I, Fischer C, Gebhard JR, Perry CM, Harkins S, Whitton JL. Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology Virology. 2000;271(2):276-288.
281. Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard JR, Whitton JL. The role of B lymphocytes in coxsackievirus B3 infection. American Journal of Pathology. 1999;155(4):1205-1215.
282. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56(5):855-865.
283. Mertens T, Pika U, Eggers HJ. Cross antigenicity among enteroviruses as revealed by immunoblot technique. Virology 1983;129(2):431-442.
284. Mintz L, Drew WL. Relation of culture site to the recovery of nonpolio enteroviruses. American Journal of Clinical Pathology. 1980;74(3):324-326.
285. Misbah SA, Spickett GP, Ryba PC, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J. Clin. Immunol. 1992;12:266-270.
286. Modlin JF, Dagan R, Berlin LE, Virshup DM, Yolken RH, Menegus M. Focal encephalitis with enterovirus infections. Pediatrics. 1991;88(4):841-845.
287. Modlin JF, Onorato IM, McBean AM, et al. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine. American Journal of Diseases of Children. 1990;144(4):480-484.
288. Moore BE, Sagik BP, Sorber CA. Procedure for the recovery of airborne human enteric viruses during spray irrigation of treated wastewater. Appl Environ Microbiol. 1979;38(4):688-693.
289. Moore M. Enteroviral disease in the United States, 1970-1979. J Infect Dis. 1982;146(1):103-108.
290. Moore M, Kaplan MH, McPhee J, Bregman DJ, Klein SW. Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79. Public Health Reports. 1984;99(5):515-522.
291. Morens DM. Enteroviral disease in early infancy. J Pediatr. 1978;92(3):374-377.
292. Morrison ME, Racaniello VR. Molecular cloning and expression of a murine homolog of the human poliovirus receptor gene. Journal of Virology. 1992;66(5):2807-2813.
293. Muir P, Nicholson F, Sharief MK, et al. Evidence for persistent enterovirus infection of the central nervous system in patients with previous paralytic poliomyelitis. Ann NY Acad Sci. 1995;753:219-232.
294. Muir P, Ras A, Klapper PE, et al. Multicenter quality assessment of PCR methods for detection of enteroviruses. J Clin Microbiol. 1999;37(5):1409-1414.
295. Mukherjee A, Morosky SA, Delorme-Axford E, et al. The Coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog. 2011;7(3):e1001311.
296. Mukherjee A, Morosky SA, Shen L, et al. Retinoic acid-induced gene-1 (RIG-I) associates with the actin cytoskeleton via caspase activation and recruitment domain-dependent interactions. Journal of Biological Chemistry. 2009;284(10):6486-6494.
297. Mulders MN, Lipskaya GY, van der Avoort HG, Koopmans MP, Kew OM, van Loon AM. Molecular epidemiology of wild poliovirus type 1 in Europe, the Middle East, and the Indian subcontinent. J Infect Dis. 1995;171(6):1399-1405.
298. Nagata N, Iwasaki T, Ami Y, et al. A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. Virology Mar 30 2004;321(1):87-100.
299. Nathanson N. The pathogenesis of poliomyelitis: what we don't know. Adv.Virus Res. 2008;71:1-50.
300. Nathanson N, Langmuir AD. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. American Journal of Hygiene. 1963;78:16-60.
301. Negishi H, Osawa T, Ogami K, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proceedings of the National Academy of Sciences, U.S.A. 2008;105(51):20446-20451.
302. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. Journal of Immunology. 1987;138:2488-2492.
303. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. Dec 1 1987;139(11):3630-3636.
304. Nielsen AC, Bottiger B, Banner J, Hoffmann T, Nielsen LP. Serious invasive Saffold virus infections in children, 2009. Emerg Infect Dis. Jan 2012;18(1):7-12.
305. Niklasson B, Kinnunen L, Hornfeldt B, et al. A new picornavirus isolated from bank voles (Clethrionomys glareolus). Virology. 1999;255(1):86-93.
306. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nature Medicine. 2009;15(7):794-797.
307. Nix WA, Berger MM, Oberste MS, et al. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method. Neurology. Apr 27 2004;62(8):1372-1377.
308. Nix WA, Jiang B, Maher K, Strobert E, Oberste MS. Identification of enteroviruses in naturally infected captive primates. J Clin Microbiol. 2008;46:2874-2878.
309. O'Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Institute Journal. 1987;14:268-275.
310. Oberste MS, Feeroz MM, Maher K, et al. Naturally acquired picornavirus infections in nonhuman primates at the Dhaka Zoo. J Virol. 2013;87(1):572-580.
311. Oberste MS, Feeroz MM, Maher K, et al. Characterizing the picornavirus landscape among synanthropic nonhuman primates in Bangladesh, 2007-2008. J Virol. 2013;87(1):558-571.
312. Oberste MS, Gotuzzo E, Blair PJ, et al. Human encephalomyocarditis virus disease in Perú. Emerg Infect Dis. 2009;15:640-646.
313. Oberste MS, Maher K, Kennett ML, et al. Molecular epidemiology and genetic diversity of echovirus type 30 (E30): genotype correlates with temporal dynamics of E30 isolation. J Clin Microbiol. 1999;37(12):3928-3933.
314. Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, Pallansch MA. Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol. 1999;37(5):1288-1293.
315. Oberste MS, Maher K, Michele SM, Belliot G, Uddin M, Pallansch MA. Enteroviruses 76, 89, 90 and 91 represent a novel group within the species Human enterovirus A. J Gen Virol. Feb 2005;86(Pt 2):445-451.
316. Oberste MS, Maher K, Pallansch MA. Complete genome sequences for nine simian enteroviruses. J Gen Virol. 2007;88:3360-3372.
317. Oberste MS, Maher K, Pallansch MA. Evidence for frequent recombination within species human enterovirus B based on complete genomic sequences of all thirty-seven serotypes. J Virol. Jan 2004;78(2):855-867.
318. Oberste MS, Maher K, Pallansch MA. Molecular phylogeny and proposed classification of the simian picornaviruses. J Virol. Feb 2002;76(3):1244-1251.
319. Oberste MS, Michele SM, Maher K, et al. Molecular identification and characterization of two proposed new enterovirus serotypes, EV74 and EV75. J Gen Virol. Nov 2004;85(Pt 11):3205-3212.
320. Oberste MS, Pallansch MA. Enterovirus molecular detection and typing. Rev Med Microbiol. 2005;16:163-171.
321. Oberste MS, Penaranda S, Maher K, Pallansch MA. Complete genome sequences of all members of the species Human enterovirus A. J Gen Virol. Jun 2004;85(Pt 6):1597-1607.
322. Oberste MS, Penaranda S, Pallansch MA. RNA recombination plays a major role in genomic change during circulation of coxsackie B viruses. J Virol. Mar 2004;78(6):2948-2955.
323. Ohka S, Matsuda N, Tohyama K, et al. Receptor (CD155)-dependent endocytosis of poliovirus and retrograde axonal transport of the endosome. Journal of Virology. 2004;78(13):7186-7198.
324. Ohka S, Sakai M, Bohnert S, et al. Receptor-dependent and -independent axonal retrograde transport of poliovirus in motor neurons. Journal of Virology. 2009;83(10):4995-5004.
325. Ohka S, Yang WX, Terada E, Iwasaki K, Nomoto A. Retrograde transport of intact poliovirus through the axon via the fast transport system. Virology 1998;250(1):67-75.
326. Olive DM, Al-Mufti S, Al-Mulla W, et al. Detection and differentiation of picornaviruses in clinical samples following genomic amplification. J Gen Virol. 1990;71(Pt 9):2141-2147.
327. Oostvogel PM, van Wijngaarden JK, van der Avoort HG, et al. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-93 [see comments]. Lancet. 1994;344(8923):665-670.
328. Otatume S, Addy P. Ecology of enteroviruses in tropics. I. Circulation of enteroviruses in healthy infants in tropical urban area. Japanese Journal of Microbiology. 1975;19(3):201-209.
329. Ozsvar Z, Deak J, Pap A. Possible role of Coxsackie-B virus infection in pancreatitis. Int. J. Pancreatol. 1992;11(2):105-108.
330. Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol. 1988;62(5):1781-1794.
331. Paul JR. A History of Poliomyelitis. New Haven: Yale University Press; 1971.
332. Peigue-Lafeuille H, Bailly JL, Aymard M, Fuchs F. Use of non-neutralizing monoclonal antibodies in an ELISA for intratypic differentiation of 28 echovirus type 25 clinical isolates. J Virol Meth. 1992;36(1):91-99.
333. Pelletier I, Duncan G, Colbere-Garapin F. One amino acid change on the capsid surface of poliovirus Sabin 1 allows the establishment of persistent infections in HEp-2c cell cultures. Virology 1998;241(1):1-13.
334. Pelletier I, Duncan G, Pavio N, Colbere-Garapin F. Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Cell Mol Life Sci. 1998;54(12):1385-1402.
335. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43(9):2109-2115.
336. Pezeshkpour GH, Dalakas MC. Pathology of spinal cord in post-poliomyelitis muscular atrophy. Birth Defects: Original Article Series. 1987;23(4):229-236.
337. Pöyry T, Kinnunen L, Hovi T, Hyypia T. Relationships between simian and human enteroviruses. J Gen Virol. 1999;80(3):635-638.
338. Prevots DR, Ciofi degli Atti ML, Sallabanda A, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis. 1998;26(2):419-425.
339. Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214(4523):916-919.
340. Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proceedings of the National Academy of Sciences of the United States of America. 1981;78(8):4887-4891.
341. Ramsingh A, Slack J, Silkworth J, Hixson A. Severity of disease induced by a pancreatropic Coxsackie B4 virus correlates with the H-2Kq locus of the major histocompatibility complex. Virus Res. 1989;14(4):347-358.
342. Ramsingh AI. Coxsackieviruses and pancreatitis. Front Biosci. 1997;2:e53-e62.
343. Ramsingh AI. CVB-induced pancreatitis and alterations in gene expression. Current Topics in Microbiology and Immunology. 2008;323:241-258.
344. Ramsingh AI, Chapman N, Tracy S. Coxsackieviruses and diabetes. Bioessays. 1997;19(9):793-800.
345. Ren R, Racaniello VR. Human poliovirus receptor gene expression and poliovirus tissue tropism in transgenic mice. J Virol. 1992;66(1):296-304.
346. Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis. 1992;166(4):747-752.
347. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 1990;63(2):353-362.
348. Rewers M, Atkinson M. The possible role of enteroviruses in diabetes mellitus. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: ASM Press; 1995:353-385.
349. Richer MJ, Fang D, Shanina I, Horwitz MS. Toll-like receptor 4-induced cytokine production circumvents protection conferred by TGF-á in coxsackievirus-mediated autoimmune myocarditis. Clin. Immunol. 2006;121(3):339-349.
350. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS ONE. 2009;4(1):e4127.
351. Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. Geographic distribution of wild poliovirus type 1 genotypes. Virology 1987;160(2):311-322.
352. Robbins FC, Enders JF, Weller TH, Florentino GL. Studies on the cultivation of poliomyelitis viruses in tissue culture. V. The direct isolation and serologic identification of virus strains in tissue culture from patients with nonparalytic and paralytic poliomyelitis. American Journal of Hygiene. 1951;54:286-293.
353. Rodriguez Cruz R. Cuba: mass polio vaccination program, 1962-1982. Reviews of Infectious Diseases. 1984;6(Suppl 2):S408-S412.
354. Roivainen M, Knip M, Hyoty H, et al. Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol. 1998;56(1):74-78.
355. Rorabaugh ML, Berlin LE, Heldrich F, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics. Aug 1993;92(2):206-211.
356. Rose NR, Herskowitz A, Neumann DA. Autoimmunity in myocarditis: models and mechanisms. Clin. Immunol. Immunopathol. 1993;68:95-99.
357. Rose NR, Herskowitz A, Neumann DA. Autoimmunity in myocarditis: models and mechanisms. Clinical Immunology & Immunopathology. 1993;68(2):95-99.
358. Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol.Life Sci. 2000;57(4):542-551.
359. Ross ME, Hayashi K, Notkins AL. Virus-induced pancreatic disease: alterations in concentration of glucose and amylase in blood. J. Infect. Dis. 1974;129(6):669-676.
360. Rotbart H. Meningitis and Encephalitis. In: Rotbart H, ed. Human enterovirus infections. Washington, DC: ASM Press; 1995:271-289.
361. Rotbart HA, Brennan PJ, Fife KH, et al. Enterovirus meningitis in adults. Clin Infect Dis. 1998;27(4):896-898.
362. Rotbart HA, O'Connell JF, McKinlay MA. Treatment of human enterovirus infections. Antiviral Res. 1998;38(1):1-14.
363. Rotbart HA, Sawyer MH, Fast S, et al. Diagnosis of enteroviral meningitis by using PCR with a colorimetric microwell detection assay. J Clin Microbiol. 1994;32(10):2590-2592.
364. Salazar-Grueso EF, Roos RP, Jubelt B, Cashman NR. Immune responses in the post-polio syndrome [letter; comment]. New England Journal of Medicine. 1992;326(9):641; discussion 642.
365. Samuelson A, Forsgren M, Johansson B, Wahren B, Sallberg M. Molecular basis for serological cross-reactivity between enteroviruses. Clinical & Diagnostic Laboratory Immunology. 1994;1(3):336-341.
366. Sandelin K, Tuomioja M, Erkkila H. Echovirus type 7 isolated from conjunctival scrapings. Scand J Infect Dis. 1977;9(2):71-73.
367. Sato S, Tsutsumi R, Burke A, et al. Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions. Journal of General Virology. 1994;75:2911-2924.
368. Satoh M, Akatsu T, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy. American Heart Journal. 2007;154(3):581-588.
369. Sawyer LA, Hershow RC, Pallansch MA, et al. An epidemic of acute hemorrhagic conjunctivitis in American Samoa caused by coxsackievirus A24 variant. American Journal of Epidemiology. 1989;130(6):1187-1198.
370. Schiff GM. Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness. Antiviral Res. 1992;17:92.
371. Schlegel A, Giddings TH, Jr., Ladinsky MS, Kirkegaard K. Cellular origin and ultrastructure of membranes induced during poliovirus infection. J Virol. 1996;70(10):6576-6588.
372. Seko Y, Ishiyama S, Nishikawa T, et al. Restricted usage of T cell receptor V alpha-V beta genes in infiltrating cells in the hearts of patients with acute myocarditis and dilated cardiomyopathy. Journal of Clinical Investigation. 1995;96(2):1035-1041.
373. Seko Y, Shinkai Y, Kawasaki A, et al. Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation. 1991;84:788-795.
374. Sharief MK, Hentges R, Ciardi M. Intrathecal immune response in patients with the post-polio syndrome [see comments]. New England Journal of Medicine. 1991;325(11):749-755.
375. Sharp DG. Multiplicity reactivation of animal viruses. Prog Med Virol. 1968;10:64-109.
376. Shindarov LM, Chumakov MP, Voroshilova MK, et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. Journal of Hygiene, Epidemiology, Microbiology & Immunology. 1979;23(3):284-295.
377. Shulman LM, Manor Y, Azar R, et al. Identification of a new strain of fastidious enterovirus 70 as the causative agent of an outbreak of hemorrhagic conjunctivitis. J Clin Microbiol. 1997;35(8):2145-2149.
378. Sicinski P, Rowinski J, Warchol JB, et al. Poliovirus type 1 enters the human host through intestinal M cells. Gastroenterology. 1990;98(1):56-58.
379. Simkova A, Petrovicova A. Experimental infection of rhesus monkeys with Coxsackie A 4 virus. Acta Virologica. 1972;16(3):250-257.
380. Simons J, Kutubuddin M, Chow M. Characterization of poliovirus-specific T lymphocytes in the peripheral blood of Sabin-vaccinated humans. J Virol. 1993;67(3):1262-1268.
381. Slifka MK, Pagarigan RR, Mena I, Feuer R, Whitton JL. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8 + T cells during picornavirus infection. Journal of Virology. 2001;75(5):2377-2387.
382. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 2006;38(6):617-619.
383. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J. Am. Coll. Cardiol. 1993;22:99A-105A.
384. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778-790.
385. Strikas RA, Anderson LJ, Parker RA. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J Infect Dis. 1986;153(2):346-351.
386. Suhy DA, Giddings TH Jr, Kirkegaard K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. Journal of Virology. 2000;74(19):8953-8965.
387. Swanink CM, Veenstra L, Poort YA, Kaan JA, Galama JM. Coxsackievirus B1-based antibody-capture enzyme-linked immunosorbent assay for detection of immunoglobulin G (IgG), IgM, and IgA with broad specificity for enteroviruses. J Clin Microbiol. 1993;31(12):3240-3246.
388. Takao S, Shimazu Y, Fukuda S, Noda M, Miyazaki K. Seroepidemiological study of human Parechovirus 1. Jpn J Infect Dis. Apr 2001;54(2):85-87.
389. Tam PE, Messner RP. Molecular mechanisms of coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution. Journal of Virology. 1999;73(12):10113-10121.
390. Tan CS, Cardosa MJ. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Archives of Virology. 2007;152(6):1069-1073.
391. Tanel RE, Kao SY, Niemiec TM, et al. Prospective comparison of culture vs genome detection for diagnosis of enteroviral meningitis in childhood. Archives of Pediatrics & Adolescent Medicine. 1996;150(9):919-924.
392. Tang TT, Sedmak GV, Siegesmund KA, McCreadie SR. Chronic myopathy associated with coxsackievirus type A9. A combined electron microscopical and viral isolation study. New England Journal of Medicine. 1975;292(12):608-611.
393. Taylor MP, Burgon TB, Kirkegaard K, Jackson WT. Role of microtubules in extracellular release of poliovirus. Journal of Virology. 2009;83(13):6599-6609.
394. Taylor MP, Kirkegaard K. Modification of cellular autophagy protein LC3 by poliovirus. Journal of Virology. 2007;81(22):12543-12553.
395. Taylor MP, Kirkegaard K. Potential subversion of autophagosomal pathway by picornaviruses. Autophagy. 2008;4(3):286-289.
396. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of future global policies for managing polioviruses. American Journal of Public Health. 2008;98:1322-1330.
397. Townsend TR, Bolyard EA, Yolken RH, et al. Outbreak of Coxsackie A1 gastroenteritis: a complication of bone-marrow transplantation. Lancet. 1982;1(8276):820-823.
398. Tracy S, Chapman NM, Romero J, Ramsingh AI. Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Trends.Microbiol. 1996;4:175-179.
399. Trask JD. Poliomyelitis virus in human stools. JAMA. 1938;111:6-11.
400. Triantafilou K, Orthopoulos G, Vakakis E, et al. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cellular Microbiology. 2005;7(8):1117-1126.
401. Triantafilou K, Triantafilou M. Coxsackievirus B4-induced cytokine production in pancreatic cells is mediated through toll-like receptor 4. Journal of Virology. 2004;78(20):11313-11320.
402. Tsao KC, Chan EC, Chang LY, et al. Responses of IgM for enterovirus 71 infection. J Med Virol. 2002;68(4):574-580.
403. Tu Z, Chapman NM, Hufnagel G, et al. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5' nontranslated region. Journal of Virology. 1995;69:4607-4618.
404. Tucker SP, Thornton CL, Wimmer E, Compans RW. Vectorial release of poliovirus from polarized human intestinal epithelial cells. J Virol. 1993;67(7):4274-4282.
405. Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6.
406. Uhlig J, Wiegers K, Dernick R. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal antibody. Virol. 1990;178(2):606-610.
407. Ursing B. Acute pancreatitis in coxsackie B infection. Br. Med. J. 1973;3(879):524-525.
408. Vekemans J, Ota MO, Wang EC, et al. T cell responses to vaccines in infants: defective IFN g production after oral polio vaccination. Clin.Exp.Immunol. 2002;127(3):495-498.
409. Vella C, Brown CL, McCarthy DA. Coxsackievirus B4 infection of the mouse pancreas: acute and persistent infection. Journal of General Virology. 1992;73(6):1387-1394.
410. Vella C, Easton AJ, Eglin RP, Brown CL, Perry L. Coxsackie virus B4 infection of the mouse pancreas: I. Detection of virus-specific RNA in the pancreas by in situ hybridisation. J. Med. Virol. 1991;35(1):46-49.
411. Vella C, Festenstein H. Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. Journal of General Virology. 1992;73(Pt 6):1379-1386.
412. Verboon-Maciolek MA, Krediet TG, Gerards LJ, de Vries LS, Groenendaal F, van Loon AM. Severe neonatal parechovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J. Feb 7 2008;27(3):241-245.
413. Vuorinen T, Kallajoki M, Hyypia T, Vainionpaa R. Coxsackievirus B3-induced acute pancreatitis: analysis of histopathological and viral parameters in a mouse model. Br J Exp Pathol. 1989;70(4):395-403.
414. Wadia NH, Katrak SM, Misra VP, et al. Polio-like motor paralysis associated with acute hemorrhagic conjunctivitis in an outbreak in 1981 in Bombay, India: clinical and serologic studies. J Infect Dis. 1983;147(4):660-668.
415. Wagner DK, Marti GE, Jaffe ES, Straus SE, Nelson DL, Fleisher TA. Lymphocyte analysis in a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency after development of echovirus dermatomyositis and meningoencephalitis. International Archives of Allergy & Applied Immunology. 1989;89(2-3):143-148.
416. Wahid R, Cannon MJ, Chow M. Virus-specific CD4 + and CD8 + cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. Journal of Virology. 2005;79(10):5988-5995.
417. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS mediate type I IFN responses to Coxsackie B virus. Journal of Virology. 2010;84(1):254-260.
418. Ward C. Severe arrhythmias in Coxsackievirus B3 myopericarditis. Arch.Dis.Child. 1978;53:174-176.
419. Weinzierl AO, Szalay G, Wolburg H, et al. Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4 - /CD8 +dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis. Journal of Virology. 2008;82(16):8149-8160.
420. Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. Journal of Virology. 1989;63(3):1338-1344.
421. Wickman I. Beitrage zur Kenntnis der Heine-Medinschen Krankheit (Poliomyelitis acuta und verwandter Erkernkungen). Berlin: Karger; 1907.
422. Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. New England Journal of Medicine. 1977;296(26):1485-1489.
423. Winther B, Farr B, Turner RB, Hendley JO, Gwaltney JM, Jr., Mygind N. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. Acta Otolaryngol. Suppl. 1984;413:19-24.
424. Winther B, Gwaltney JM, Jr., Mygind N, Hendley JO. Viral-induced rhinitis. Am. J. Rhinol. 1998;12(1):17-20.
425. Wolthers KC, Benschop KS, Schinkel J, et al. Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis. Aug 1 2008;47(3):358-363.
426. Wong CY, Woodruff JJ, Woodruff JF. Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. III. Role of sex. J Immunol. 1977;119(2):591-597.
427. Wong J, Zhang J, Si X, et al. Autophagosome supports coxsackievirus B3 replication in host cells. Journal of Virology. 2008;82(18):9143-9153.
428. Woodruff JF. Viral myocarditis. A review. American Journal of Pathology. 1980;101(2):425-484.
429. Woodruff JF, Woodruff JJ. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. Journal of Immunology. 1974;113:1726-1734.
430. World Health Organization. Global Polio Eradication Initiative. 2012. http://www.polioeradication.org/.
431. World Health Organization. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). Geneva: World Health Organization, 2011.
432. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE. 2008;3(10):e3433.
433. Wu X, Zhao T, Tian Y. [A bivalent VP1 gene vaccine against Coxsackie virus B1/B3]. Zhonghua Yi Xue Za Zhi. Apr 25 2001;81(8):480-484.
434. Wyatt HV. Poliomyelitis in the fetus and the newborn. A comment on the new understanding of the pathogenesis. Clinical Pediatrics. 1979;18(1):33-38.
435. Xatzipsalti M, Kyrana S, Tsolia M, et al. Rhinovirus viremia in children with respiratory infections. Am. J. Respir. Crit Care Med. 2005;172(8):1037-1040.
436. Yagi S, Schnurr D, Lin J. Spectrum of monoclonal antibodies to coxsackievirus B-3 includes type- and group-specific antibodies. J Clin Microbiol. 1992;30(9):2498-2501.
437. Yamashita T, Sakae K, Tsuzuki H, et al. Complete nucleotide sequence and genetic organization of Aichi virus, a distinct member of the Picornaviridae associated with acute gastroenteritis in humans. J Virol. 1998;72(10):8408-8412.
438. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature Medicine. 2009;15(7):798-801.
439. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol. Aug 2003;77(15):8366-8377.
440. Yang WX, Terasaki T, Shiroki K, et al. Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor. Virol. 1997;229(2):421-428.
441. Yin-Murphy M. Acute hemorrhagic conjunctivitis. Prog Med Virol. 1984;29:23-44.
442. Yin-Murphy M, Abdul Rahim N, Phoon MC, Baharuddin I, Howe J. Early and rapid diagnosis of acute haemorrhagic conjunctivitis with tear specimens. Bulletin of the World Health Organization. 1985;63(4):705-709.
443. Ylipaasto P, Klingel K, Lindberg AM, et al. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia. Feb 2004;47(2):225-239.
444. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. New England Journal of Medicine. 1979;300(21):1173-1179.
445. Yoon JW, London WT, Curfman BL, Brown RL, Notkins AL. Coxsackie virus B4 produces transient diabetes in nonhuman primates. Diabetes. 1986;35(6):712-716.
446. Young DC, Sharp DG. Partial reactivation of chlorine-treated echovirus. Appl Environ Microbiol. 1979;37(4):766-773.
447. Yousef GE, Isenberg DA, Mowbray JF. Detection of enterovirus specific RNA sequences in muscle biopsy specimens from patients with adult onset myositis. Annals of the Rheumatic Diseases. 1990;49(5):310-315.
448. Yu CK, Chen CC, Chen CL, et al. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J. Biomed. Sci. 2000;7(6):523-528.
449. Zaoutis T, Klein JD. Enterovirus infections. Pediatrics in Review. 1998;19(6):183-191.
450. Zhang A, Nanni RG, Oren DA, Rozhon EJ, Arnold E. Three-dimensional structure-activity relationships for antiviral agents that interact with picornavirus capsids. Seminars in Virology. 1992;3(6):453-471.
451. Zhang G, Haydon DT, Knowles NJ, McCauley JW. Molecular evolution of swine vesicular disease virus. J Gen Virol. 1999;80(Pt 3):639-651.
452. Zhang S, Racaniello VR. Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. J Virol. 1997;71(7):4915-4920.
453. Zheng DP, Zhang LB, Fang ZY, et al. Distribution of wild type 1 poliovirus genotypes in China. J Infect Dis. Dec 1993;168(6):1361-1367.
454. Ziegler JB, Penny R. Fatal echo 30 virus infection and amyloidosis in X-linked hypogammaglobulinemia. Clinical Immunology & Immunopathology. 1975;3(3):347-352.
455. Zoll J, Galama J, Melchers W. Intratypic genome variability of the coxsackievirus B1 2A protease region. J Gen Virol. 1994;75(Pt 3):687-692.